Tmem178 linked to bone inflammation

Science Signaling published an April 2026 paper describing how Tmem178 acts as a brake on inflammatory signaling in bone-resorbing cells. The study, led by Khushpreet Kaur and colleagues, found that Tmem178 suppresses activation of the NLRP3 inflammasome in osteoclasts by restricting calcium influx. The authors reported that when that restraint was lost, inflammatory signaling increased and bone loss worsened in mouse models. An X post linking the paper circulated on Friday, May 22, drawing wider attention to the findings. ### Which bone cells are actually involved here? The April 2026 paper focused on osteoclasts, not osteoblasts. Osteoclasts are the cells that break down bone during normal remodeling, while osteoblasts build new bone matrix. The Science Signaling authors wrote that activation of the NLRP3 inflammasome can drive bone resorption in inflammatory conditions and identified Tmem178 as an inhibitor of that process. Caroline Schmidt and Ulf Wagner, writing in a Science Signaling focus article on the study, said osteoclasts operate in a calcium-rich environment during bone resorption and still avoid triggering excessive inflammasome activity. They said the work showed osteoclasts limit calcium influx through Tmem178, protecting bone from inflammatory over-resorption. (science.org) ### What did the researchers say Tmem178 is doing? Kaur and co-authors reported that Tmem178 restrains calcium fluxes by limiting store-operated calcium entry, or SOCE. In the paper’s summary, they said Tmem178 was abundant in osteoclasts and suppressed nucleation of the NLRP3 inflammasome. They also wrote that osteoclasts lacking Tmem178, or wild-type osteoclasts exposed to high calcium concentrations, showed robust inflammasome activation. (science.org) The companion focus article said Tmem178 is an endoplasmic reticulum membrane protein that inhibits STIM1 and therefore SOCE. Schmidt and Wagner wrote that this limits rises in cytosolic calcium and suppresses inflammasome assembly during osteoclast differentiation. ### What evidence linked that pathway to bone damage? The Science Signaling paper reported that inflammasome formation increased in vivo under conditions where osteoclasts efficiently released calcium from bone. (science.org) The authors also said deletion of Nlrp3 rescued the osteopenic phenotype seen in Tmem178-deficient mice. That result linked the inflammatory pathway to bone loss, rather than only to a cell-culture effect. (science.org) The study summary said NLRP3 abundance gradually decreased during osteoclastogenesis but could be restored by lipopolysaccharide, or LPS. LPS and nigericin activated the inflammasome in macrophages, the authors wrote, but not in osteoclasts or lineage-committed precursors unless the Tmem178-dependent restraint was removed. ### Why did this paper surface again on May 22? (science.org) An X post on May 22 linked to the paper and described it as a finding about Tmem178 stopping bone-cell inflammation and damage, according to the social briefing provided for this story. The underlying paper itself was published in April 2026, so Friday’s activity was a recirculation of peer-reviewed research rather than a same-day journal release. (science.org) ### What comes next from here? The paper’s own framing points to the next step: testing whether the Tmem178-calcium-NLRP3 pathway can be targeted in diseases marked by inflammatory bone loss. The Science Signaling focus article said the findings have implications for conditions in which excessive osteoclast activity damages bone. The study remains available through Science Signaling, where the April 2026 article and the accompanying focus piece name Kaur, Gabriel Mbalaviele and their co-authors as the key participants. (science.org)